Immunic Transfers to Nasdaq Capital Market After Failing Bid Price Rule, Eyes Reverse Split

summarizeSummary

Immunic, Inc. has transferred its common stock listing to the Nasdaq Capital Market after failing to meet the $1.00 minimum bid price requirement, receiving an extended grace period but committing to a reverse stock split if necessary.

check_boxKey Events · Corporate Governance and Compliance · IMUX

• Listing Transfer Approved

  Immunic received approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective January 7, 2026.

• Non-Compliance with Bid Price Rule

  The company failed to regain compliance with Nasdaq's $1.00 minimum bid price rule by the December 24, 2025 deadline.

• Extended Grace Period Granted

  The transfer provides Immunic with an additional 180-day grace period, until June 22, 2026, to meet the $1.00 bid price requirement.

• Potential Reverse Stock Split

  As a condition of approval, Immunic notified Nasdaq that it would seek to implement a reverse stock split if necessary to regain compliance.

auto_awesomeAnalysis · IMUX · Life Sciences

Immunic's transfer to the Nasdaq Capital Market, while preventing immediate delisting, signals ongoing challenges with its stock valuation and compliance. The failure to meet the $1.00 minimum bid price rule for an extended period indicates a lack of investor confidence or significant operational hurdles. Moving to a lower-tier market can sometimes impact institutional investor interest and liquidity. The company's commitment to a reverse stock split, if necessary, is a strong negative signal, as such actions are often viewed as a last resort to maintain listing and can be followed by further price declines.